Pulmonx Corp
About Pulmonx Corp
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $90.5M
- Net income
- -$54.0M
- Total assets
- $129.3M
- Market cap
- $64.6M
- Gross margin
- 74.2%
- Operating margin
- -59.3%
- Net margin
- -59.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $90.5M
- Cost of revenue
- $23.4M
- Gross profit
- $67.1M
- Operating expenses
- $120.8M
- Operating income
- -$53.7M
- Income tax
- $626.0K
- Net income
- -$54.0M
- EPS (basic)
- $-1.33
- EPS (diluted)
- $-1.33
Balance sheet
- Total assets
- $129.3M
- Current assets
- $101.7M
- Total liabilities
- $75.2M
- Current liabilities
- $20.1M
- Shareholders’ equity
- $54.1M
Cash flow
- Operating cash flow
- -$32.4M
- Investing cash flow
- $30.5M
- Financing cash flow
- $833.0K
- Net cash flow
- -$1.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $64.6M
- EPS (diluted)
- $-1.33
- Shares outstanding
- 43.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 1, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $54.0M in FY2025.
- Revenue grew 87% from FY2021 to FY2025.
- Gross margin of 74.2%, net margin -59.7%.
- Trading 61% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Pulmonx Corp.
Write a review
News about Pulmonx Corp
News & sentiment via Polygon.io
